Search for a trial

A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the
efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk patients with
chronic lymphocytic leukemia following first-line therapy

To compare the efficacy and safety of lenalidomide versus placebo maintenance therapy (standard care).

Does antenatal allopurinol during perinatal asphyxia reduce post-hypoxic-ischemic reperfusion damage in the newborn? A double blind randomised placebo controlled multicenter trial.

In the present proposal, we aim to answer whether antenatal allopurinol administration does reduce hypoxic-ischaemic encephalopathy in neonates exposed to intra-uterine asphyxia.